{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:31:43Z","timestamp":1792315903630,"version":"4.4.0"},"reference-count":45,"publisher":"Informa Healthcare","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2016,5,3]]},"DOI":"10.1185\/03007995.2016.1140030","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T11:55:31Z","timestamp":1452254131000},"page":"817-827","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy"],"prefix":"10.1185","volume":"32","author":[{"given":"B. Douglas","family":"Smith","sequence":"first","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Harvard University, Cambridge, MA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Latremouille-Viau","sequence":"additional","affiliation":[{"name":"Analysis Group Inc., Montreal, Quebec, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[{"name":"Analysis Group Inc., Montreal, Quebec, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Harvard University, Cambridge, MA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3197","published-online":{"date-parts":[[2016,2,10]]},"reference":[{"key":"CIT0001","unstructured":"National Cancer Institute. Chronic Myelogenous Leukemia Treatment (PDQ). US Department of Health and Human Services, 2015. Available at: http:\/\/www.cancer.gov\/types\/leukemia\/patient\/cml-treatment-pdq#section\/all [Last accessed 26 May 2015]"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.240"},{"key":"CIT0003","unstructured":"Novartis Pharmaceuticals Corporation. GLEEVEC (imatinib mesylate) tablets for oral use. US Food and Drug Administration, 2015. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021588s042lbl.pdf [Last accessed 26 May 2015]"},{"key":"CIT0004","unstructured":"Bristol-Myers Squibb Company. Sprycel Prescribing Information. US Food and Drug Administration, 2014. Available at: http:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf [Last accessed 26 May 2015]"},{"key":"CIT0005","unstructured":"Novartis Pharmaceutical Corp. Tasigna Prescribing Information. US Food and Drug Administration, 2015. Available at: https:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/tasigna.pdf [Last accessed 26 May 2015]"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv048"},{"key":"CIT0007","volume-title":"Leukemia, SEER Cancer Statistics Review, 1975\u20132011","author":"Howlader N","year":"2014"},{"key":"CIT0008","volume-title":"Chronic Myeloid Leukemia \u2013 SEER Stat Fact Sheets","author":"National Cancer Institute.","year":"2015"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0207-7"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.533648"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.18553\/jmcp.2014.20.10.1006","volume":"20","author":"Trivedi D","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.649849"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.705264"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.789012"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.041251"},{"key":"CIT0016","volume-title":"The International Classification of Diseases: 9th Revision, Clinical Modification: ICD-9-CM","author":"National Center for Health Statistics (US).","year":"1991","edition":"4"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199611000-00004"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725060-00004"},{"key":"CIT0021","volume-title":"Consumer Price Index (CPI)","author":"US Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes.","year":"2014"},{"key":"CIT0022","unstructured":"Elixhauser A, Kruzikas D, Steiner C. Comorbidity Software Documentation. US Agency for Healthcare Research and Quality, 2004. Available at: http:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/comorbidity\/comorbidity.jsp [Last accessed 18 August 2015]"},{"key":"CIT0023","doi-asserted-by":"crossref","unstructured":"Coutre PD, Turkina A, Kim D, Ceglarek B. Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study. In: Blood 2009:abstract 3286. Available at: https:\/\/ash.confex.com\/ash\/2009\/webprogram\/Paper19517.html","DOI":"10.1182\/blood.V114.22.3286.3286"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25656"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.12341"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.168"},{"key":"CIT0027","author":"Baccarani M","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7146"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-358135"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.058776"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23938"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12102"},{"key":"CIT0034","volume-title":"Chronic myelogenous leukemia, v1.2015","author":"National Comprehensive Cancer Network (NCCN).","year":"2014"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70579-5"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0088-6"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.2165\/11591840-000000000-00000"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1769-2"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-513937"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.153"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21184"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.2174\/15680096113139990090"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-546705"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.4065\/84.2.161"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1043-8"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007995.2016.1140030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T01:57:57Z","timestamp":1599443877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007995.2016.1140030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,10]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5,3]]}},"alternative-id":["10.1185\/03007995.2016.1140030"],"URL":"https:\/\/doi.org\/10.1185\/03007995.2016.1140030","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}